FPRX Five Prime Therapeutics, Inc.

48.62
+0  (0%)
Previous Close 48.62
Open 50.20
Price To book 3.27
Market Cap 1.32B
Shares 27,138,000
Volume 311,089
Short Ratio 6.50
Av. Daily Volume 393,016

SEC filingsSee all SEC filings

  1. 8-K - Current report 17516066
  2. 8-K - Current report 162047390
  3. 8-K - Current report 162040687
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161973537
  5. 8-K - Current report 161971805

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dose expansion phase initiated May 2016. Enrollment to be completed 2H 2017. Data due 2017.
FPA008
Pigmented Villonodular Synovitis (PVNS)
Phase 1b NSCLC halted, mesothelioma to continue. Data due at ESMO 8-12 September 2017. Exact date TBC.
FP-1039
Mesothelioma cancer

Latest News

  1. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu
  2. Blog Coverage Five Prime Announced Extension of Collaboration Agreement by Bristol-Myers Squibb
  3. Bristol-Myers Extends Deal with Five Prime Therapeutics
  4. Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
  5. Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
  6. Five Prime Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  7. Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : December 13, 2016
  8. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
  9. Is TASER International, Inc. (TASR) Firing Blanks?
  10. ETFs with exposure to Five Prime Therapeutics, Inc. : December 8, 2016
  11. FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  12. Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy?
  13. Five Prime Presents Data from FPA144 in Urothelial Cancer at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapies
  14. Five Prime Therapeutics to Host Research & Development Day on December 8, 2016
  15. Five Prime Therapeutics to Host Research & Development Day on December 8, 2016
  16. ETFs with exposure to Five Prime Therapeutics, Inc. : November 28, 2016
  17. Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 16, 2016
  18. FIVE PRIME THERAPEUTICS INC Financials
  19. Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting Demonstrating Potent Anti-Tumor Activity with Novel Tetravalent Anti-GITR Antibody
  20. Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting Demonstrating Potent Anti-Tumor Activity with Novel Tetravalent Anti-GITR Antibody

SEC Filings

  1. 8-K - Current report 17516066
  2. 8-K - Current report 162047390
  3. 8-K - Current report 162040687
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161973537
  5. 8-K - Current report 161971805
  6. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 161971726
  7. RW - Registration Withdrawal Request 161970013
  8. CT ORDER - Confidential treatment order 161892135
  9. 8-K - Current report 161885140
  10. CT ORDER - Confidential treatment order 161882732